Special issues in the management of infective endocarditis caused by gram-positive cocci (Q34715626)

4 August 2017

1 reference

title

Special issues in the management of infective endocarditis caused by gram-positive cocci (English)

1 reference

4 August 2017

main subject

gram-positive bacteria

0 references

infective endocarditis

1 reference

Bruno Hoen

1

1 reference

4 August 2017

publication date

1 June 2002

1 reference

Infectious Disease Clinics of North America

4 August 2017

published in

1 reference

4 August 2017

volume

16

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

437-52, xi

1 reference

The Gulstonian Lectures, on Malignant Endocarditis

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Characteristics of infective endocarditis in France in 1991. A 1-year survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Clinical and morphological characteristics in Streptococcus bovis endocarditis: a comparison with other causative microorganisms in 177 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Is the clinical spectrum and prognosis of native valve infective endocarditis in non-addicts changing?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Glycopeptide tolerance in bacteria causing endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Prosthetic-valve endocarditis caused by penicillin-resistant Streptococcus mitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and cefotaxime

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and ceftriaxone

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Antimicrobial susceptibility of Abiotrophia adiacens and Abiotrophia defectiva

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

PCR for detection and identification of Abiotrophia spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin-and glycopeptide-resistant isolate of Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Review of pneumococcal endocarditis in adults in the penicillin era.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Streptococcus pneumoniae Endocarditis in Adults: A Multicenter Study in France in the Era of Penicillin Resistance (1991-1998)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Austrian syndrome caused by highly penicillin-resistant Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Infective endocarditis caused by highly penicillin-resistant Streptococcus pneumoniae: successful treatment with cefuzonam, ampicillin and imipenem

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Endocarditis caused by drug-resistant Streptococcus pneumoniae in a child

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Infective endocarditis caused by Streptococcus pneumoniae with high-level resistance to penicillin and cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of experimental endocarditis due to penicillin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Infective endocarditis caused by beta-hemolytic streptococci. The Infectious Diseases Society of America's Emerging Infections Network

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cádiz

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Once-daily aminoglycosides in the treatment of gram-positive endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Outpatient intravenous antibiotic therapy for endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Staphylococcus epidermidis endocarditis treated with RP 59500 (quinapristin/dalfopristin)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Efficacy of linezolid in a staphylococcal endocarditis rabbit model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

In vivo activities of evernimicin (SCH 27899) against vancomycin-susceptible and vancomycin-resistant enterococci in experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2801%2900004-6

7 January 2021

10.1016/S0891-5520(01)00004-6

Identifiers

DOI

1 reference

4 August 2017

1 reference